NDC-1308 DUAL MECHANISM OF ACTION


R

NDC-1308

Dual Mechanism of Action Up-regulates Key Genes Required for Remyelination
NDC-1308

ENDECE Approach To Remyelination


ENDECE has discovered and is developing NDC-1308, a new therapy with a dual mechanism of action (MOA) designed to provide the necessary anti-inflammatory, pro-repair environment at lesions and upregulate genes necessary for inducing OPCs to differentiate into mature oligodendrocytes responsible for remyelination.

For more information go to About NDC-1308


R
Upregulates key genes within oligodendrocyte progenitor cells (OPCs) necessary for inducing OPCs to differentiate into mature oligodendrocytes which restore and maintain myelin sheaths.
R
Up-regulates lipoprotein lipase (LPL) expression causing a polarization in macrophages from the pro-inflammatory M1-like state to the anti-inflammatory, pro-repair state M2-like phenotype.

NDC-1308 Induces Remyelination at the Gene Transcription Level


Mechanism 1

NDC-1308 Upregulates Key Genes Required for OPC Differentiation Into Mature Oligodendrocytes.


Mechanism 2

Upregulating LPL Causes Polarization of Macrophages to M2 State.

NDC-1308
NDC-1308
Remyelination at the Gene Transcription



NDC-1308

A new drug with a unique dual mechanism of action (MOA) for inducing remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis, neuromyelitis optica, and osmotic demyelination syndrome.


To learn more go to Developing NDC-1308


To request more information go to: